Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

Background CheckMate 025 has shown superior efficacy for nivolumab over everolimus in patients with advanced renal cell carcinoma (aRCC) along with improved safety and tolerability. This analysis assesses the long‐term clinical benefits of nivolumab versus everolimus. Methods The randomized, open‐la...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Cancer Ročník 126; číslo 18; s. 4156 - 4167
Hlavní autoři:	Motzer, Robert J., Escudier, Bernard, George, Saby, Hammers, Hans J., Srinivas, Sandhya, Tykodi, Scott S., Sosman, Jeffrey A., Plimack, Elizabeth R., Procopio, Giuseppe, McDermott, David F., Castellano, Daniel, Choueiri, Toni K., Donskov, Frede, Gurney, Howard, Oudard, Stéphane, Richardet, Martin, Peltola, Katriina, Alva, Ajjai S., Carducci, Michael, Wagstaff, John, Chevreau, Christine, Fukasawa, Satoshi, Tomita, Yoshihiko, Gauler, Thomas C., Kollmannsberger, Christian K., Schutz, Fabio A., Larkin, James, Cella, David, McHenry, M. Brent, Saggi, Shruti Shally, Tannir, Nizar M.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Wiley Subscription Services, Inc 15.09.2020
Témata:	advanced renal cell carcinoma (aRCC) Antiangiogenics Cancer CheckMate 025 Clear cell-type renal cell carcinoma everolimus Fatigue immune checkpoint inhibitor Immune checkpoint inhibitors Immunotherapy Inhibitor drugs Kidney cancer Kidneys Monoclonal antibodies nivolumab Oncology Patients previously treated Pruritus Quality of life Randomization Renal cell carcinoma Safety Safety management Stomatitis Survival Targeted cancer therapy Toxicity previously treated CheckMate 025 advanced renal cell carcinoma (aRCC) everolimus immune checkpoint inhibitor nivolumab
ISSN:	0008-543X, 1097-0142, 1097-0142
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!